Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

home / peer-exchange / advances-in-cdk4-6-inhibitor-use-in-high-risk-early-breast-cancer-2024-updates

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, leads an expert panel in a discussion highlighting recent updates for use of CDK4/6 inhibitors in high-risk early breast cancer.

Episodes

Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

June 26th 2024EP. 1: Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

Fact checked by:

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, from Mayo Clinic opens a conversation around CDK4/6 inhibitor prescription for patients diagnosed with early breast cancer.

Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

June 26th 2024EP. 2: Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

Fact checked by:

Results from the monarchE trial are analyzed by Hope Rugo, MD, and Joyce O'Shaughnessy, MD.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo